---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-270328"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2026-06-15T12:15:16+00:00"
generated_at: "2026-06-15T12:20:33.726914+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neumora discontinues navacaprant after Phase 3 MDD failures; cuts workforce 35%

## Summary
- Navacaprant failed primary endpoint in KOASTAL-2 (p=0.813) and KOASTAL-3 (p=0.480); development discontinued.
- Company reducing workforce ~35%, expects ~$10M annualized savings, ~$2M restructuring costs in Q2 2026.
- Cash and cash equivalents expected to fund operations into Q3 2027.
- Pipeline focus shifts to NMRA-511 (Alzheimer's agitation), NMRA-898 (schizophrenia), NMRA-215 (obesity) with multiple milestones in H2 2026.
- Third Amendment to loan agreement extends interest-only period; minimum liquidity covenant tied to milestones or market cap effective July 1, 2026.

## SEC filing metadata
- accession: 0001193125-26-270328
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2026-06-15T12:15:16+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/0001193125-26-270328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/d943192d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-270328
- JSON: https://secwatch.observer/filing/0001193125-26-270328.json
- Plain text: https://secwatch.observer/filing/0001193125-26-270328.txt

## Key facts
- Material Agreements
  Neumora Therapeutics, Inc. amended Third Amendment to the Loan and Security Agreement with K2 HealthVentures LLC (effective 2026-06-10).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: K2 HealthVentures LLC
  - Effective: 2026-06-10
  source text: On June 10, 2026, Neumora Therapeutics, Inc. (the “Company” or “Neumora”) as borrower, entered into a Third Amendment to the Loan and Security Agreement (the “Third Amendment”), with K2 HealthVentures LLC as a lender, and the lenders party thereto from time to time (collectively, “Lenders”, and each, a “Lender”), and K2 HealthVentures LLC, as administrative agent for Lenders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/0001193125-26-270328-index.htm
- Restructurings & Charges
  Neumora Therapeutics, Inc. announced a restructuring with charges of approximately $2 million (approximately 35%).
  - Type: restructuring
  - Charge: approximately $2 million
  - Headcount: approximately 35%
  source text: On June 12, 2026, in connection with the discontinuation of development of navacaprant described below, the Company implemented a reduction in force of approximately 35%, which it expects to complete in the second and third quarters of 2026. The Company expects the reduction in force to result in an annualized cost savings of approximately $10 million, partially offset by one-time restructuring costs of approximately $2 million to be incurred in the second quarter of 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/0001193125-26-270328-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.